PRN: Research and Markets - Global Intravenous Iron Drugs Market - Analysis, Technologies & Forecasts to 2021 - Key Vendors are Allergan, AMAG Pharmaceuticals, Daiichi Sankyo, Galenica & Pharmacosmos

27/apr/2017 11:15:10 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Research and Markets - Global Intravenous Iron Drugs Market - Analysis, Technologies & Forecasts to 2021 - Key Vendors are Allergan, AMAG Pharmaceuticals, Daiichi Sankyo, Galenica & Pharmacosmos

 
[27-April-2017]
 

DUBLIN, Apr. 27, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Intravenous Iron Drugs Market 2017-2021" report to their offering.

Research and Markets Logo

The global IV iron drugs market to grow at a CAGR of 10.46% during the period 2017-2021.

The report, Global IV Iron Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

According to the report, the market has witnessed a shift from conventional dextran intravenous iron drugs to non-dextran intravenous iron drugs. The increased demand for these drugs is attributed to their ability to deliver larger doses of iron in a short time. Furthermore, ferric carboxymaltose is preferred over iron polymaltose for outpatients as it can be managed easily. Injectafer/Ferinject is the first non-dextran product indicated for the treatment of anemia. This drug is manufactured and marketed by Galenica (outside the US and Canada) and Daiichi Sankyo (the US and Canada). Galenica's Ferinject reported sales of $261.14 million in 2015, indicating an increase of 26.8% over that in previous fiscal year.

Daiichi Sankyo's Injectafer posted sales of $155 million in 2015, reflecting a YoY growth of 124.6%. Injectafer/Ferinject addresses challenges such as intolerance or unsatisfactory response, safety concerns, and dosing and compliance issues associated with conventional iron therapies. Injectafer/Ferinject contains ferric carboxymaltose, which is a stable complex and possesses very low immunogenic potential. Therefore, it does not pose the risk of anaphylactic reactions. Furthermore, these drugs allow the administration of large doses in a single and rapid session without the requirement of a test dose. Such advantages will drive the adoption of non-dextran therapies for the treatment of anemia.

Key vendors

  • Allergan
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • Galenica
  • Pharmacosmos

Other prominent vendors

  • Nippon Shinyaku
  • NOXXON Pharma
  • Rockwell Medical
  • Sanofi
  • Wanbang Biopharmaceutical

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview of iron deficiency

PART 06: Pipeline landscape

PART 07: Market landscape

PART 08: Market segmentation by product type

PART 09: Geographical segmentation

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/vsms5m/global

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl